LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression.

    Ong, David S Y / Chong, Ga-Lai M / Chemaly, Roy F / Cremer, Olaf L

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2022  Volume 28, Issue 10, Page(s) 1335–1344

    Abstract: Background: Cytomegalovirus (CMV) infection is a well-recognised complication of solid organ and hematopoietic cell transplantation. However, CMV infection also occurs in patients with human immunodeficiency virus infection, previously immunocompetent ... ...

    Abstract Background: Cytomegalovirus (CMV) infection is a well-recognised complication of solid organ and hematopoietic cell transplantation. However, CMV infection also occurs in patients with human immunodeficiency virus infection, previously immunocompetent intensive care unit patients, and individuals on immunosuppressive medications for various underlying diseases.
    Objectives: This review describes the comparative effects of CMV infection in distinct types of acquired immunosuppression.
    Sources: Selected peer-reviewed publications on CMV infections published until December 2021.
    Content: CMV infection affects various organ systems through direct cytolytic mechanisms but may also exert indirect effects by promoting pro-inflammatory and immunosuppressive responses. This has been well studied in transplant recipients, for whom antiviral prophylaxis and pre-emptive therapy have now become standard practice. These strategies not only prevent direct CMV disease manifestations but also mitigate various immunopathological processes to reduce graft-vs.-host disease, graft rejection, and the occurrence of secondary bacterial and fungal infections. The efficacy of neither prophylactic nor pre-emptive treatment of CMV infection has been demonstrated for patients with critical illness- or medication-induced immunosuppression. Many observational studies have shown an independent association between CMV reactivation and a prolonged duration of mechanical ventilation or increased mortality in the intensive care unit. Furthermore, data suggest that CMV reactivation may increase pulmonary inflammation and prolong the duration of mechanical ventilation.
    Implications: A large number of observational and experimental studies suggest attributable morbidity and mortality related to CMV infection, not only in transplant recipients and patients with human immunodeficiency virus infection but also in patients with critically illness- or medication-induced immunosuppression. Adequately powered randomised controlled trials investigating the efficacy of prophylaxis or pre-emptive treatment of CMV infection in these patients are lacking, with a notable exception for transplant recipients.
    MeSH term(s) Antiviral Agents/therapeutic use ; Cytomegalovirus Infections ; Graft Rejection ; Humans ; Immunosuppression Therapy ; Transplant Recipients
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2022-06-13
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2022.05.034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Painful and swollen tongue: mucosal leishmaniasis due to Leishmania infantum.

    Chong, Ga-Lai M / Ong, David S Y / de Mendonça Melo, Mariana / van Hellemond, Jaap J

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2021  Volume 113, Page(s) 109–112

    Abstract: Background: Leishmaniasis is a parasitic disease caused by different Leishmania species. L. infantum is found in the Mediterranean area. It usually causes visceral or cutaneous leishmaniasis, but rarely mucosal leishmaniasis (ML).: Methods: A 62-year- ...

    Abstract Background: Leishmaniasis is a parasitic disease caused by different Leishmania species. L. infantum is found in the Mediterranean area. It usually causes visceral or cutaneous leishmaniasis, but rarely mucosal leishmaniasis (ML).
    Methods: A 62-year-old man with metastatic non-small-cell lung carcinoma visited the outpatient clinic because of a painful and swollen tongue. Initially, oral candidiasis was suspected and patient was unsuccessfully treated accordingly. Subsequently, a biopsy from the tongue was taken.
    Results: Histology of the tongue biopsy showed an inflammation with histiocytes and Leishmania amastigotes. Molecular analysis determined these parasites as L. donovani complex. Based on the patient's travel history, ML caused by L. infantum was diagnosed.
    Conclusion: ML is an unusual presentation of L. infantum. ML is not only caused by Leishmania species endemic in Latin America, but also should be considered in the differential diagnosis for European patients. A biopsy of the affected location is needed to confirm the diagnosis.
    MeSH term(s) Carcinoma, Non-Small-Cell Lung ; Humans ; Leishmania infantum ; Leishmaniasis, Cutaneous ; Leishmaniasis, Visceral ; Lung Neoplasms ; Male ; Middle Aged ; Tongue
    Language English
    Publishing date 2021-09-29
    Publishing country Canada
    Document type Case Reports ; Journal Article
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2021.09.071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales.

    Jacob, Ann-Sophie / Chong, Ga-Lai / Lagrou, Katrien / Depypere, Melissa / Desmet, Stefanie

    The Journal of antimicrobial chemotherapy

    2021  Volume 76, Issue 12, Page(s) 3317–3318

    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Cephalosporins ; Microbial Sensitivity Tests ; beta-Lactamases/genetics ; Cefiderocol
    Chemical Substances Anti-Bacterial Agents ; Cephalosporins ; beta-Lactamases (EC 3.5.2.6)
    Language English
    Publishing date 2021-08-24
    Publishing country England
    Document type Letter
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkab304
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.

    Chong, Ga-Lai M / Broekman, Fleur / Polinder, Suzanne / Doorduijn, Jeanette K / Lugtenburg, Pieternella J / Verbon, Annelies / Cornelissen, Jan J / Rijnders, Bart J A

    International journal of antimicrobial agents

    2015  Volume 46, Issue 1, Page(s) 82–87

    Abstract: Chemotherapy-induced neutropenia can be complicated by invasive pulmonary aspergillosis (IPA). In 2008, liposomal amphotericin B (L-AmB) inhalation was shown to prevent IPA in a placebo-controlled trial. Patients with acute myeloid leukaemia (AML) are ... ...

    Abstract Chemotherapy-induced neutropenia can be complicated by invasive pulmonary aspergillosis (IPA). In 2008, liposomal amphotericin B (L-AmB) inhalation was shown to prevent IPA in a placebo-controlled trial. Patients with acute myeloid leukaemia (AML) are the subset of haematology patients at high risk for IPA. In 2008, L-AmB inhalation prophylaxis became the standard of care for all AML patients in Erasmus MC. In this study, the efficacy and cost effectiveness of L-AmB inhalation were evaluated in a prospective cohort of AML patients. In total, 127 consecutive AML patients received chemotherapy and prophylactically inhaled L-AmB during their first and second chemotherapy cycles; 108 patients treated for AML at the same sites from 2005-2008 served as controls. A standardised diagnostic protocol was used and probable/proven IPA served as the primary endpoint. Diagnostic and therapeutic costs were also comprehensively analysed and compared. A significant decrease in probable/proven IPA in the L-AmB inhalation group was observed (L-AmB 9.5% vs. controls 23.4%; P=0.0064). Systemic antifungal therapy given at any time during the entire AML therapy decreased from 52.8% to 29.9%. Per-patient equipment and drug costs for L-AmB inhalation (1292 €/patient) were more than compensated for by a decrease in costs for diagnostics and therapeutic voriconazole use (-1816 €/patient). No serious adverse events related to L-AmB inhalation were observed. In an unselected AML patient group, L-AmB inhalation resulted in a significant and substantial decrease in IPA and was cost saving. Now that azole resistance is more frequent, non-azole-based prophylaxis may become an attractive strategy.
    MeSH term(s) Administration, Inhalation ; Adult ; Aerosols/administration & dosage ; Aerosols/adverse effects ; Aerosols/economics ; Aged ; Amphotericin B/administration & dosage ; Amphotericin B/adverse effects ; Amphotericin B/economics ; Antifungal Agents/administration & dosage ; Antifungal Agents/adverse effects ; Antifungal Agents/economics ; Aspergillosis/economics ; Aspergillosis/prevention & control ; Chemoprevention/adverse effects ; Chemoprevention/economics ; Chemoprevention/methods ; Cost-Benefit Analysis ; Diagnostic Tests, Routine/economics ; Diagnostic Tests, Routine/methods ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Humans ; Leukemia, Myeloid, Acute/complications ; Male ; Middle Aged ; Netherlands ; Prospective Studies ; Treatment Outcome ; Young Adult
    Chemical Substances Aerosols ; Antifungal Agents ; liposomal amphotericin B ; Amphotericin B (7XU7A7DROE)
    Language English
    Publishing date 2015-07
    Publishing country Netherlands
    Document type Clinical Study ; Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2015.02.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life

    Chong, Ga-Lai M / Annelies Verbon / Bart J.A. Rijnders / Fleur Broekman / Jan J. Cornelissen / Jeanette K. Doorduijn / Pieternella J. Lugtenburg / Suzanne Polinder

    International journal of antimicrobial agents. 2015 July, v. 46, no. 1

    2015  

    Abstract: Chemotherapy-induced neutropenia can be complicated by invasive pulmonary aspergillosis (IPA). In 2008, liposomal amphotericin B (L-AmB) inhalation was shown to prevent IPA in a placebo-controlled trial. Patients with acute myeloid leukaemia (AML) are ... ...

    Abstract Chemotherapy-induced neutropenia can be complicated by invasive pulmonary aspergillosis (IPA). In 2008, liposomal amphotericin B (L-AmB) inhalation was shown to prevent IPA in a placebo-controlled trial. Patients with acute myeloid leukaemia (AML) are the subset of haematology patients at high risk for IPA. In 2008, L-AmB inhalation prophylaxis became the standard of care for all AML patients in Erasmus MC. In this study, the efficacy and cost effectiveness of L-AmB inhalation were evaluated in a prospective cohort of AML patients. In total, 127 consecutive AML patients received chemotherapy and prophylactically inhaled L-AmB during their first and second chemotherapy cycles; 108 patients treated for AML at the same sites from 2005–2008 served as controls. A standardised diagnostic protocol was used and probable/proven IPA served as the primary endpoint. Diagnostic and therapeutic costs were also comprehensively analysed and compared. A significant decrease in probable/proven IPA in the L-AmB inhalation group was observed (L-AmB 9.5% vs. controls 23.4%; P=0.0064). Systemic antifungal therapy given at any time during the entire AML therapy decreased from 52.8% to 29.9%. Per-patient equipment and drug costs for L-AmB inhalation (1292 €/patient) were more than compensated for by a decrease in costs for diagnostics and therapeutic voriconazole use (−1816 €/patient). No serious adverse events related to L-AmB inhalation were observed. In an unselected AML patient group, L-AmB inhalation resulted in a significant and substantial decrease in IPA and was cost saving. Now that azole resistance is more frequent, non-azole-based prophylaxis may become an attractive strategy.
    Keywords amphotericin B ; aspergillosis ; breathing ; cost effectiveness ; diagnostic techniques ; disease control ; drug therapy ; drugs ; equipment ; hematology ; myeloid leukemia ; neutropenia ; patients ; protocols ; risk
    Language English
    Dates of publication 2015-07
    Size p. 82-87.
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2015.02.023
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  6. Article ; Online: Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid.

    Chong, Ga-Lai M / van de Sande, Wendy W J / Dingemans, Gijs J H / Gaajetaan, Giel R / Vonk, Alieke G / Hayette, Marie-Pierre / van Tegelen, Dennis W E / Simons, Guus F M / Rijnders, Bart J A

    Journal of clinical microbiology

    2015  Volume 53, Issue 3, Page(s) 868–874

    Abstract: Azole resistance in Aspergillus fumigatus is increasingly reported. Here, we describe the validation of the AsperGenius, a new multiplex real-time PCR assay consisting of two multiplex real-time PCRs, one that identifies the clinically relevant ... ...

    Abstract Azole resistance in Aspergillus fumigatus is increasingly reported. Here, we describe the validation of the AsperGenius, a new multiplex real-time PCR assay consisting of two multiplex real-time PCRs, one that identifies the clinically relevant Aspergillus species, and one that detects the TR34, L98H, T289A, and Y121F mutations in CYP51A and differentiates susceptible from resistant A. fumigatus strains. The diagnostic performance of the AsperGenius assay was tested on 37 bronchoalveolar lavage (BAL) fluid samples from hematology patients and 40 BAL fluid samples from intensive care unit (ICU) patients using a BAL fluid galactomannan level of ≥1.0 or positive culture as the gold standard for detecting the presence of Aspergillus. In the hematology and ICU groups combined, there were 22 BAL fluid samples from patients with invasive aspergillosis (IA) (2 proven, 9 probable, and 11 nonclassifiable). Nineteen of the 22 BAL fluid samples were positive, according to the gold standard. The optimal cycle threshold value for the presence of Aspergillus was <36. Sixteen of the 19 BAL fluid samples had a positive PCR (2 Aspergillus species and 14 A. fumigatus samples). This resulted in a sensitivity, specificity, and positive and negative predictive values of 88.9%, 89.3%, 72.7%, and 96.2%, respectively, for the hematology group and 80.0%, 93.3%, 80.0%, and 93.3%, respectively, in the ICU group. The CYP51A real-time PCR confirmed 12 wild-type and 2 resistant strains (1 TR34-L98H and 1 TR46-Y121F-T289A mutant). Voriconazole therapy failed for both patients. The AsperGenius multiplex real-time PCR assay allows for sensitive and fast detection of Aspergillus species directly from BAL fluid samples. More importantly, this assay detects and differentiates wild-type from resistant strains, even if BAL fluid cultures remain negative.
    MeSH term(s) Antifungal Agents/pharmacology ; Aspergillus/drug effects ; Aspergillus/isolation & purification ; Azoles/pharmacology ; Bronchoalveolar Lavage Fluid/microbiology ; Cytochrome P-450 Enzyme System/genetics ; Female ; Fungal Proteins/genetics ; Humans ; Invasive Pulmonary Aspergillosis/diagnosis ; Invasive Pulmonary Aspergillosis/microbiology ; Male ; Microbiological Techniques/methods ; Molecular Diagnostic Techniques/methods ; Multiplex Polymerase Chain Reaction/methods ; Mutant Proteins/genetics ; Mutation, Missense ; Predictive Value of Tests ; Real-Time Polymerase Chain Reaction/methods ; Retrospective Studies ; Sensitivity and Specificity
    Chemical Substances Antifungal Agents ; Azoles ; Fungal Proteins ; Mutant Proteins ; Cytochrome P-450 Enzyme System (9035-51-2) ; cytochrome P-450 CYP51A, Aspergillus (EC 1.14.14.-)
    Language English
    Publishing date 2015-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Validation Studies
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/JCM.03216-14
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top